BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29861382)

  • 1. Clinical significance of the TNF-α receptors, TNFRSF2 and TNFRSF9, on cell migration molecules Fascin-1 and Versican in acute leukemia.
    El Kramani N; Elsherbiny NM; El-Gayar AM; Ebrahim MA; Al-Gayyar MMH
    Cytokine; 2018 Nov; 111():523-529. PubMed ID: 29861382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of PIM-2 and NF-κB genes is increased in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and is associated with complete remission rate and overall survival.
    Kapelko-Słowik K; Urbaniak-Kujda D; Wołowiec D; Jaźwiec B; Dybko J; Jakubaszko J; Słowik M; Kuliczkowski K
    Postepy Hig Med Dosw (Online); 2013 Jun; 67():553-9. PubMed ID: 23752607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased Regulatory T Cells in Peripheral Blood of Acute Myeloid Leukemia Patients Rely on Tumor Necrosis Factor (TNF)-α-TNF Receptor-2 Pathway.
    Wang M; Zhang C; Tian T; Zhang T; Wang R; Han F; Zhong C; Hua M; Ma D
    Front Immunol; 2018; 9():1274. PubMed ID: 29922294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
    Pituch-Noworolska A
    Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution of the cytoskeletal protein, Nestin, in acute leukemia.
    Du X; Yang XH; Wu YF; Liang J; Zhang J; Huang ZC; Zhu ZP; Lin W; Zou MX; Wen JY; Wu SJ; Guo R; Zhang XM; Lahn BT; He F; Xiang AP
    Biotech Histochem; 2015 Jul; 90(5):384-94. PubMed ID: 25839093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.
    Fröhlich A; Loick S; Bawden EG; Fietz S; Dietrich J; Diekmann E; Saavedra G; Fröhlich H; Niebel D; Sirokay J; Zarbl R; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
    EBioMedicine; 2020 Feb; 52():102647. PubMed ID: 32028068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome.
    Badar T; Shetty A; Bueso-Ramos C; Cortes J; Konopleva M; Borthakur G; Pierce S; Huang X; Chen HC; Kadia T; Daver N; Dinardo C; O'Brien S; Garcia-Manero G; Kantarjian H; Ravandi F
    Am J Hematol; 2015 Sep; 90(9):769-73. PubMed ID: 26017166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implications of angiogenic factors in patients with acute or chronic leukemia: hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia.
    Kim JG; Sohn SK; Kim DH; Baek JH; Lee NY; Suh JS; Chae SC; Lee KS; Lee KB
    Leuk Lymphoma; 2005 Jun; 46(6):885-91. PubMed ID: 16019534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.
    Mustjoki S; Sidenius N; Sier CF; Blasi F; Elonen E; Alitalo R; Vaheri A
    Cancer Res; 2000 Dec; 60(24):7126-32. PubMed ID: 11156421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics of versican-expressing macrophages in bone marrow after cord blood stem cell transplantation for treatment of acute myelogenous leukaemia.
    Senda M; Fukuyama R; Nagasaka T
    J Clin Pathol; 2016 Oct; 69(10):906-11. PubMed ID: 26951084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Plasma concentration of the shed form of L-selectin (sL-selectin) in patients with acute myeloblastic leukemia (AML) and acute lymphoblastic leukemia (ALL) and its relation to the clinical course].
    Kapelko-Slowik K; Jaźwiec B; Mirosław S; Wołowiec D; Urbaniak-Kujda D; Tomaszewska-Toporska B; Potoczek S; Ciszak L; Kuliczkowski K
    Pol Arch Med Wewn; 2004 Nov; 112(5):1283-8. PubMed ID: 15773509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
    Zhang TJ; Lin J; Zhou JD; Li XX; Zhang W; Guo H; Xu ZJ; Yan Y; Ma JC; Qian J
    Gene; 2018 Jan; 640():79-85. PubMed ID: 29032147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NPM1 alternative transcripts are upregulated in acute myeloid and lymphoblastic leukemia and their expression level affects patient outcome.
    Handschuh L; Wojciechowski P; Kazmierczak M; Marcinkowska-Swojak M; Luczak M; Lewandowski K; Komarnicki M; Blazewicz J; Figlerowicz M; Kozlowski P
    J Transl Med; 2018 Aug; 16(1):232. PubMed ID: 30126426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of 4-1BB and its ligand on blasts correlates with prognosis of patients with AML.
    Schmohl JU; Nuebling T; Wild J; Kroell T; Kanz L; Salih HR; Schmetzer H
    J Investig Med; 2016 Dec; 64(8):1252-1260. PubMed ID: 27388616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High levels of the shed form of L-selectin are present in patients with acute leukemia and inhibit blast cell adhesion to activated endothelium.
    Spertini O; Callegari P; Cordey AS; Hauert J; Joggi J; von Fliedner V; Schapira M
    Blood; 1994 Aug; 84(4):1249-56. PubMed ID: 7519478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of new markers discriminating between myeloid and lymphoid acute leukemia.
    Haouas H; Haouas S; Uzan G; Hafsia A
    Hematology; 2010 Aug; 15(4):193-203. PubMed ID: 20670477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Necrosis Factor Receptor Type 1-Associated Death Domain Protein Is a Potential Prognostic Biomarker in Acute Myeloid Leukemia.
    Xiao Y; Geng Z; Deng T; Wang D; Jiang L
    Am J Med Sci; 2019 Feb; 357(2):111-115. PubMed ID: 30665491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects.
    Wellbrock J; Latuske E; Köhler J; Wagner K; Stamm H; Vettorazzi E; Vohwinkel G; Klokow M; Uibeleisen R; Ehm P; Riecken K; Loges S; Thol F; Schubert C; Amling M; Jücker M; Bokemeyer C; Heuser M; Krauter J; Fiedler W
    Clin Cancer Res; 2015 May; 21(10):2388-98. PubMed ID: 25745035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression of p16INK4a, p15INK4b, p21WAF1/Clip1 cell cycle inhibitors on blastic cells in patients with acute myeloblastic leukemia (AML) and acute lymphoblastic leukemia (ALL) ].
    Kapelko-Słowik K; Wołowiec D; Sedek K; Jaźwiec B; Urbaniak-Kujda D; Kuliczkowski K
    Pol Arch Med Wewn; 2002 Sep; 108(3):849-53. PubMed ID: 12600181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endocan, a potential prognostic and diagnostic biomarker of acute leukemia.
    Xu Z; Zhang S; Zhou Q; Wang Y; Xia R
    Mol Cell Biochem; 2014 Oct; 395(1-2):117-23. PubMed ID: 24934240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.